Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Account Payables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Account Payables for 11 consecutive years, with -$3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 183.97% to -$3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.3 million, a 540.25% decrease, with the full-year FY2024 number at -$2.3 million, down 53.22% from a year prior.
  • Change in Account Payables was -$3.6 million for Q3 2025 at Editas Medicine, down from $1.3 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.4 million in Q2 2024 to a low of -$7.0 million in Q4 2024.
  • A 5-year average of -$151526.3 and a median of -$229000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 196.29% in 2023, then soared 1161.95% in 2024.
  • Editas Medicine's Change in Account Payables stood at $1.8 million in 2021, then soared by 46.49% to $2.7 million in 2022, then crashed by 196.29% to -$2.6 million in 2023, then plummeted by 169.81% to -$7.0 million in 2024, then soared by 49.12% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Change in Account Payables are -$3.6 million (Q3 2025), $1.3 million (Q2 2025), and -$27000.0 (Q1 2025).